DDR2 and hepatocellular carcinoma: Mutations and increased expression of DDR2 have been reported in Hodgkin's Lymphoma and anaplastic large cell lymphoma [41], lung squamous cell carcinoma [42], nasopharyngeal carcinoma [43], sarcoma [44], hepatocellular carcinoma [45], aneuploid papillary thyroid cancer [46] and non-small cell lung cancer [47].